Lanean...
A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer’s disease
OBJECTIVE: In patients with Alzheimer’s disease (AD) with psychosis or agitation that respond to haloperidol treatment, to evaluate the risk of relapse following discontinuation. METHODS: In outpatients with AD with symptoms of psychosis or agitation, responders to 20 weeks of haloperidol (0.5 to 5...
Gorde:
| Egile Nagusiak: | , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2010
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3685500/ https://ncbi.nlm.nih.gov/pubmed/21845596 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/gps.2630 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|